diverse tumour cell lines in vitro (Schiller et al, 1994) . Moreover, patients with acute promyelocytic leukaemia have been found to enter remission after oral administration of ATRA (Castaigne et al, 1990) . We have previously reported that ATRA has a dose-dependent and reversible antiproliferative action in four human ovarian carcinoma cell lines (Caliaro et al, 1994) . The morphological and biochemical changes associated with this antiproliferative effect were consistent with the induction of a differentiation pathway.
ATRA has been shown to increase the sensitivity of a murine embryonal carcinoma cell line to CDDP (Guchelaar et al, 1993) and to potentiate the cytotoxicity of CDDP, etoposide and bleomycin in a human ovarian teratocarcinoma (Le Ruppert et al, 1992) . Furthermore, the combination of ATRA and CDDP has been reported to be beneficial in the treatment of head and neck tumours (Sacks et al, 1995) . Fenretinide, a synthetic retinoid, has also been shown to enhance the anti-tumour activity of CDDP against a human ovarian carcinoma cell line xenografted in nude mice (Formelli et al, 1993) .
In the present study, we evaluated the nature of interactions between ATRA and CDDP on various ovarian carcinoma cell lines and attempted to determine the molecular mechanisms underlying the modulation of CDDP cytotoxicity by this retinoid.
MATERIALS AND METHODS Drugs, chemicals, enzymes and molecular reagents
All the agents used in this work were purchased from Sigma (Coger, Paris, France).
Cell lines
The human ovarian carcinoma cell lines used for this study included five serous cell lines: NIHOVCAR3 (ATCC, HTB161), OVCCR, (Jozan et al, 1992) , 2008 and its cisplatin-resistant subline 2008/C13* (a generous gift from Dr Stephen Howell, University of California, San Diego, La Jolla, CA USA) and A2780 (Behrens et al, 1987) and two endometrioid cell lines: IGROV, (a generous gift from Dr J Benard, Villejuif, France) and SKOV3 (ATCC, HTB77).
The cells were grown in RPMI-1640 medium supplemented with 5% fetal calf serum (FCS), 2 mM glutamine (Seromed, Polylabo, Strasbourg, France), 2 ng ml-' epidermal growth factor (Boehringer Mannheim, Germany) and 5 gg ml-' insulin in humidified 5% carbon dioxide/95% air at 370C. CDDP cytotoxicity assays CDDP cytotoxicity was measured by clonogenic assay on plastic. The cells were plated to obtain about 200 control colonies for each cell line. After plating, the cells were treated for a single doubling time with a suitable concentration of ATRA, based on their respective sensitivities to this agent (IC30). Then, they were incubated for 1 h with various concentrations of CDDP. The cells were washed and left to form colonies in the presence of the same concentration of ATRA.
The time course of the ATRA effect was evaluated in experiments on NIHOVCAR3 cells. Two days after plating, the cells were treated with ATRA for different times exposure (0, 6, 12, 24 , and 48 h) and then with CDDP IC50 for h. The medium was then renewed, and they were left to form colonies in the presence of ATRA.
Median effect analysis
Median effect analysis was used to establish the interactions between ATRA and CDDP only in OVCCR,,NIHOVCAR3 and IGROV, cells, according to Chou and Talalay (1984) . The combination index (CbI) was determined using a clonogenic assay on plastic at increasing level of cell kill with the same schedule as for CDDP cytotoxicity assays except that ATRA and CDDP were combined in a fixed concentration ratio corresponding to the ratio of the individual IC50 (w/w) for each cell line (ATRA-CDDP), i.e.
3:10 for OVCCR, cells and 1:10 for NIHOVCAR3 cells. For IGROVI cells, the ratio was fixed to 300:25.
For the molecular mechanism studies of ATRA action on CDDP sensitivity, only two cell lines were used -one sensitive to its antiproliferative effect, NIHOVCAR3, and one insensitive to it, IGROVI cells. The concentration used was 106 M ATRA.
Platinum accumulation
For platinum accumulation, the cells growing in the log phase in 10-cm-diameter Petri dishes were treated during one doubling time with 106 M ATRA. They were then incubated with their IC50 CDDP. At the end of this incubation, the IGROV, and NIHOVCAR3 cell lines were harvested by trypsinization, rinsed with phosphate-buffered saline (PBS), counted and centrifuged at 300 g. The final pellet was reconstituted with water and frozen at -20°C. On the day of assay, the cells were thawed and disrupted by sonication, and the platinum concentration was determined in the samples by flameless atomic absorption spectrophotometry.
Total GSH concentration and glutathione S-Transferase (GST) activity IGROVI and NIHOVCAR3 cells were incubated with 10-M ATRA for their respective doubling time. They were then changed for a new medium with ATRA (Oh). Glutathione (GSH) and GST activity were determined in cytosolic fractions from lysed cells at 0, 4, 8, 12, 24 and 48 h after the second addition of ATRA, using, respectively, the kinetic assay of Akerboom et al (1981) and the method described by Habig et al (1974) as previously described (Nehme et al, 1994 Miller et al (1988) , and the experiments were made as previously described (Nehme et al, 1994) .
PKC activity involvement in CDDP sensitization
In this study, we looked for the possible modulation of PKC in these cell lines, using TPA (12-O-tetradecanoyl phorbol 13 (Table 1) . Likewise, differences in sensitivity to the antiproliferative effect of ATRA (Caliaro et al, 1994) were observed; three cell lines were insensitive to ATRA, two had weak sensitivity and only NIHOVCAR3and OVCCR, had an IC50 of 5xjO-7M. DNA platinum adducts formation under ATRA treatment
As the critical intracellular target for cisplatin is reported to be the DNA, we examined the formation and the evolution of total platinum-DNA adducts under ATRA treatment. Figure 4 shows the data obtained in NIHOVCAR3 cells treated as described in 'Materials and methods'. ATRA increases the total DNA adducts formation in this cell line and this increase persists for 48 h, whereas no modulation is observed in IGROV1 cells (6.8 + 0.8 vs 7.02 ±1.4 ng of Pt per mg of DNA for control cells, data not shown). It is interesting to note that no DNA repair in control cells, estimated from the ratio of loss of platinum, could be observed for 48 h in NIHOVCAR3 cells.
PKC activity involvement in sensitization to CDDP by ATRA Protein kinase C has been shown to be involved in sensitization of cells to CDDP, but the exact mechanism (activation or inhibition) remains to be elucidated. In this work, we looked for the modulation of CDDP cytotoxicity using TPA, the principal PKC modulator, and determined the kinetic activation of this kinase in NIHOVCAR3 cells using this phorbol ester. We then investigated the influence of ATRA.
It can be seen from Figure 5A that TPA altered PKC activity in NIHOVCAR3 cells. A fast activation was observed during a 2-min exposure to TPA followed by an inactivation for 5 min. Moreover, in clonogenic assay, TPA leads potentiation of CDDP cytotoxicity regardless of the time of pretreatment with this phorbol ester, i.e. 5 min, 1 h or 24 h ( Figure 5B ).
ATRA treatment had different effects in the two cell lines (Figure 6 ). In IGROVI cells, which are insensitive to its antiproliferative effect and for which no potentiation is obtained, there is an increase in both cytosolic and membrane PKC activity at 30 min exposure to 1O0M ATRA, followed by a slow decrease. In NIHOVCAR3 cells, there is a decrease in both cytosolic and membrane PKC activity for 20 min, followed by an increase in activity in the two fractions. In this cell line, PKC activity is stimulated late by ATRA (at 24 h).
Modulation of EGF receptor expression under ATRA treatment A transient increase (2.6-fold) of EGFR mRNA level was observed at 12 h ( Figure 7A ) in NIHOVCAR3 cells, whereas an inhibition was reported for IGROVI cells as early as 12 h with a maximum at 24 h (45%). This inhibition remains constant for 72 h ( Figure 7B ). An increase (three-fold) is also observed for sensitive OVCCR, cells at 24 h (data not shown).
DISCUSSION
In this study, we reported that the antiproliferative effect of the retinoid ATRA is associated with its ability to increase CDDP cytotoxicity in various human ovarian carcinoma cell lines in vitro. Interestingly, it also enhanced CDDP cytotoxicity in the CDDP-resistant cell line 2008/C 13*. These observations suggest that ATRA might help overcome CDDP resistance and prolong survival in patients with certain types of ovarian cancer. In fact, the level of CDDP resistance that occurs in patients is quite low. vivo is less than twice that of parental cells before treatment with CDDP. This weak resistant level is compatible with ATRA capacity to increase CDDP cytotoxicity. The combination effect of ATRA and CDDP treatment on ovarian adenocarcinoma cell proliferation could be owing to an enhancement of CDDP cytotoxicity by ATRA or to an elevation of the antiproliferative action of ATRA in the presence of CDDP. Therefore, the potentiation of ATRA was only observed in OVCCRI, NIHOVCAR3, 2008/C 13* and SKOV3 ovarian adenocarcinoma cells which are all responsive to the antiproliferative effect of ATRA. These results support the hypothesis that ATRA modulates CDDP cytotoxicity. This effect on ovarian carcinoma cell proliferation was only observed when ATRA was added before CDDP and for a duration corresponding to the doubling time of the different ovarian adenocarcinoma cells. For NIHOVCAR3 cells, the optimal effect was observed at 48 h. These results are in line with those previously reported for small-cell lung cancer (Doyle et al, 1989) , for an ovarian teratocarcinoma (Le Ruppert et al, 1992) , for a murine embryonal carcinoma cell line (Guchelaar et al, 1993) and for epidermoid carcinoma (Sacks et al, 1995) . Taken together, these observations suggest that ATRA induces a cascade of events facilitating CDDP cytotoxicity.
The nature of the interaction evaluated according to the method of Chou and Talalay (1984) (Nehme et al, 1994) in the same cell lines and for IL-la-CDDP for NIHOVCAR3 cells (Benchekroun et al, 1993) . Moreover, we can note that this synergy is more important, when it is present, in NIHOVCAR3 than in OVCCRI cells whatever the association, i.e. ATRA-CDDP or INFy-CDDP. These results suggest that interaction between CDDP and biological response modifiers could be cell line dependent.
The enhancement of CDDP cytotoxicity by ATRA could stem from a variety of molecular mechanisms.
One possibility is that the increase in intracellular accumulation of CDDP leads to sensitization. IL-la (Benchekroun et al, 1993) , forskolin (Mann et al, 1991) and amphotericin B (Morikage et al, 1993) all increase platinum accumulation and enhance the cytotoxic effect of CDDP. In this present work, we found that ATRA does not modify the platinum accumulation regardless of the sensitivity of the cells to this agent. Similarly, ATRA was not found to alter platinum accumulation in a murine embryonal carcinoma cell line (Guchelaar et al, 1993) .
The second possibility is that ATRA has an influence on cell detoxification systems, such as GSH and GST activity and metallothionein. Indeed, the intracellular levels of GSH and GST have been reported to influence sensitivity to CDDP (Chen et al, 1989) . We only observed a transient decrease in the GSH content after treatment of NIHOVCAR3 cells with ATRA. This would probably not be sufficient to potentiate CDDP cytotoxicity as it has been shown that only prolonged GSH depletion could sensitize human ovarian carcinoma cells to CDDP cytotoxicity (Andrews et al, 1988) . We found that ATRA decreased GST activity in NIHOVCAR3 cells, whereas it had no influence on this activity in IGROV, cells. GSTi is the only isoenzyme of GST expressed in these ovarian cell lines (Nehme et al, 1995) , and it has been reported that GSTir transcription in simian virus-transformed human keratinocytes is regulated by retinoids (Xia et al, 1993) .
The correlation between the increase in CDDP cytotoxicity and the decrease in GST activity found in NIHOVCAR3 cells is in favour of a role of GST modulation in the sensitization of ovarian carcinoma cells to CDDP.
A third possibility could be the interaction with the DNA repair of cells treated with CDDP. In this study, ATRA increased the total DNA adduct number at 0, 24 and 48 h after CDDP treatment, and this increase remained constant throughout the experiment. These results suggest that NIHOVCAR3 cells do not repair its DNA adducts for 48 h and that the kinetics of repair are not affected by ATRA. It was reported that the persistence of an increased number of adducts could be involved in the sensitivity of cells to CDDP (Bedford et al, 1988) . Moreover, a correlation was shown between the number of adducts in leucocytes and monocytes DNA of patients treated with CDDP and the clinical response to it (Reed et al, 1987) . All these results confirm the hypothesis that the increased number of total DNA adducts (1.5-fold) in ATRAtreated cells could be implicated in the potentiation of CDDP cytotoxicity.
A fourth possibility is an involvement of PKC in the ATRAinduced increase in CDDP toxicity. Indeed, several studies have indicated a role for PKC activity in the sensitization to CDDP (Hofmann et al, 1988; Isonishi et al, 1990; Hirata et al, 1993; Basu et al, 1994 ). An inhibition or an activation of PKC in CDDP sensitization appears to depend on cell type. There is recent evidence for a role of PKC in the signalling of ATRA-induced terminal differentiation before activation of the nuclear receptor RAR, (Kurie et al, 1993a ). In addition, there is evidence for cooperation between the signalling pathways of retinoids and PKC activators (Kurie et al, 1993b , Bouzinba-Segard et al, 1994 . We therefore have investigated the possible implication of PKC in ATRAenhanced CDDP cytotoxicity. We found that PKC was activated by ATRA regardless of the sensitivity of the cell line to its antiproliferative effect. However, the time course of the activation differed between cell lines (compare NIHOVCAR3 and IGROV, ) and in NIHOVCAR3 cells differed from that induced by TPA.
These results are not consistent with a direct involvement of PKC in the CDDP sensitization by ATRA in these cell lines.
The last possibility could be the EGFR pathway. Indeed, ATRA increases the mRNA level of this receptor in NIHOVCAR3 and OVCCRI cells, and this modulation is accompanied by a sensitization of these cell lines to CDDP, whereas in IGROVI cells an opposite effect is observed. These results suggest a possible implication of the EGFR pathway in the potentiation of CDDP cytotoxicity in these cells. Although the modulation of EGFR protein remains to be studied, similar results were obtained in the tumour necrosis factor (TNF)-resistant cell line ME180 R which has an increasing sensitivity to CDDP (Nishikawa et al, 1992) and a more important expression of EGF receptor protein. Moreover, Christen et al (1990) have also shown that the CDDP sensitivity of cells are dependent upon the number of EGF receptors.
In this study, we have shown that a pretreatment with ATRA potentiates the CDDP cytotoxicity of cells sensitive to its antiproliferative effect. The molecular mechanism involved in this synergy is probably multifactorial. The ability of ATRA to decrease GST activity and to increase the total DNA adducts might contribute directly to the enhancement of CDDP cytotoxicity. Moreover an implication of the EGFR pathway might also be considered. Although the exact mechanism of this ATRA potentiation is not totally elucidated, the present results are in line with those of Formelli et al (1993) who suggested in an in vivo study that differentiation-inducing agents, such as all-trans retinoic acid, might enhance the therapeutic efficiency of CDDP in human ovarian adenocarcinoma.
